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MAKEUP CALL: HOW COSMETIC PRODUCT USE AFFECTS
WOMEN ABSENT FEDERAL REGULATION
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B. Cosmetics Affect Women More Than They Affect Men
C. Adversely Affected Women Currently Have Limited
Options in Seeking Legal Recourse Without Federal
Cosmetics Regulation
Ill. THE LACK OF FD&C ACT REGULATION OVER COSMETICS HAS A
DISPARATE IMPACT ON WOMEN
IV. THE COSMETICS INDUSTRYS CURRENT SELF-REGULATION
REGIME DOES NOT CURE THIS DISPARATE IMPACT; THUS,
ADDITIONAL FEDERAL REGULATION IS NEEDED
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Personal Care Products Safety Act
Safe Cosmetics Modernization Act
FDA Cosmetic Safety and Modernization Act of 2017
The Personal Care Products Safety Act Has the Greatest
Potential to Address the Current Disparate Impact on
Women and Should Thus Become the New FDA
Cosmetics Regulatory Regime

CONCLUSION
INTRODUCTION
The lack of federal cosmetics regulation by the U.S. Food and
Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (FD&C Act) has a disparate impact on women. The scarcity
of federal cosmetics regulation and its biased effect on women are
further accentuated when viewed in comparison to the extent of the
FD&C Act's food and drug regulations, as well as in light of cosmetics
research and reports conducted over the past eighty years. Statistics
show that women use more cosmetic products than men overall. 1
1. See, e.g., Rebecca Adams, This Is Why It's More Expensive to Be a Woman, HUFFINGTON POST (Sept. 23, 2013), http://www.huffingtonpost.com/2013/09/23/beauty-products

_n_3975209.html [https://perma.ccJLB23-3AQE].
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The lack of federal cosmetics regulation thus results in the FD&C
Act being gender-biased by not offering the users of cosmetic products (i.e., women) the same protections provided to both men and
women in the regulation of the FD&C Act's other two jurisdictional
industries-food and drugs.2
Part I of this Note analyzes the FD&C Act provisions regulating
cosmetics and contrasts them with the far more extensive regulations over food and drugs. It also explores the legislative history of
the FD&C Act in an attempt to answer the question of why there is
comparatively so little federal cosmetics regulation. Part II takes an
in-depth look at cosmetics-what they are, how they affect women
as their core users more so than men, and the limited legal remedies
that exist. Part III then argues the lack of cosmetics regulation under
the FD&C Act results in a disparate impact on women as cosmetic
products' main users, which must be remedied with new federal
cosmetics legislation. Finally, Part IV asserts the claim that the
gender bias stemming from this lack of cosmetics regulation under
the FD&C Act is not cured by the cosmetic industry's self-regulation, and instead requires additional provisions to be amended to
the cosmetics subchapter of the FD&C Act. This final part explores
three pieces oflegislation that are currently in front of Congress and
the industry's response to their provisions.
I. CONTRASTING COSMETICS REGULATION IN THE FD&C
ACT TO THAT OF FOOD AND DRUGS TO ESTABLISH A
LACK OF COSMETICS REGULATION

A. Federal Food, Drug, and Cosmetic Act Regulation of Cosmetics
Versus its Regulation of Food and Drugs
The scope of cosmetics regulation under the FD&C Act is far less
expansive than regulations of both food and drugs, which captures
more nuances in those industries than the cosmetics subchapter. 3
Cosmetics regulation spans a mere three sections of the entire Act:
(1) what constitutes an adulterated cosmetic, (2) what constitutes a
misbranded cosmetic, and (3) a note on regulations making exemptions to any aforementioned cosmetic labeling requirement. 4 These
2. Compare 21 U.S.C.A. §§ 361-63 (West 1993) (cosmetic regulations under FD&C
Act), with 21 U.S.C.A. §§ 341-501-1 (West 1993) (food regulations under FD&C Act), and
21 U.S.C.A. §§ 351-60fff-7 (West 2017) (drug regulations under FD&C Act).
3. Compare21 U.S.C.A. §§ 361-63 (West 1993), with 21 U.S.C.A. §§ 341-501-1 (West
1993); see also 21 U.S.C.A. 351-60fff-7 (West 2017).
4. 21 U.S.C.A. §§ 361-63.
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sections are not extensive: the longest section, the misbranding provision, contains only six subsections, which are each only-at mostseveral lines long. 5 Perhaps most notably absent are provisions
outlining any FDA approval or notification processes for cosmetic
products and their ingredients, 6 other than requiring pre-market
approval for color additives contained in cosmetics. 7
Analyzing the provisions regulating food and drugs under the
FD&C Act further emphasizes the major deficiency in federal cosmetics regulation.8 The FD&C Act's subchapter on food contains
twenty-seven sections in addition to three sections analogous to those
regulating cosmetics. 9 The food adulteration and misbranding provisions are also more comprehensive with many more definitions
and nuances. 10 The presence of over two dozen additional sections
provides more guidance and awareness ofthe law and further demonstrates the depth of regulation that the FDA via the FD&C Act has
over food versus cosmetics. 11
The FD&C Act food subchapter features provisions governing
such specificities as bottled water and infant formula.12 Although
there are obvious human health and safety concerns that lead to
regulating the food industry in this in-depth manner, 13 cosmetics do
not garner the same relative protections. 14
Drugs under the FD&C Act are regulated even more exhaustively than food. 15 The drug subchapter is divided into nine parts with
a total of over one hundred governing provisions.16 These again include the same three analogous cosmetics provisions, which here have
a multitude of nuanced subsections. 17 As with food, the health and
safety rationale behind these provisions is clear, but sharpens the contrast with regard to the comparative lack of cosmetics regulation. 18
5. See id. § 362.
6. See id. §§ 361--63.
7. FDA Authority over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are
FDA-Regulated, U.S. FOOD & DRUG ADMIN., http://www .fda.gov/Cosmetics /GuidanceReg
ulation/LawsRegulations/ucm074162.htm [https://perma.ccfl'8GV-QX8W] [hereinafter

FDA Authority over Cosmetics].
8 . See 21 U.S.C.A. §§ 351--60fff-7 (West 2017); see also 21 U .S.C.A. §§ 341-501-1.
9 . See §§ 341--501-1.
10. Id. §§ 342-43.
11. §§ 361--63; see also§§ 341-501-1.
12. §§ 349, 350a.
13. See David F . Cavers, The Food, Drug, and Cosmetic Act of 1938: Its Legislative
History and Its Substantive Provisions, 6 L. & CONTEMP. PROBS. 2, 3 (1939).
14. See 21 U.S.C.A. §§ 361--63 (West 1993).
15. See§§ 351--60fff-7; see also§§ 341--501-1.
16. See§§ 351--60fff-7.
17. See§§ 351-53.
18. See Cavers, supra note 13, at 3.
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Throughout the rest of the FD&C Act, beyond the cosmetics
subchapter, the FDA has been given the legal authority to inspect
cosmetic facilities as well as imported cosmetics. 19 This authorization is given in tandem with the right of the FDA to also inspect
food, drug, device, and tobacco product facilities. 20 Despite this afterthe-fact mechanism for regulation, however, the FD&C Act requires
no pre-market approval for cosmetics or cosmetic ingredients (with
the exception of color additives), and leaves the safety determination
to the manufacturer. 21 As the FDA explains, "[c]ompanies and individuals who manufacture or market cosmetics have a legal responsibility to ensure the safety of their products. Neither the law nor FDA
regulations require specific tests to demonstrate [that] safety ....
The law also does not require cosmetic companies to share their
safety information with FDA." 22 The FDA can, and does, issue nonbinding guidance documents that advise cosmetics manufacturers
on a number of topics from general good manufacturing practices to
more specific topics, such as the recommended maximum level of
lead in lipstick. 2 s Notwithstanding these suggestions, guidance
documents do not confer rights on or limit manufacturers, nor do
they give legal authority to the FDA. 24 Manufacturers are still free
to use alternative approaches as long as they do not violate the
applicable law, in other words, the FD&C Act. 25 The cosmetics industry, thus, is the party responsible for ensuring product safety,
and no specific rules exist to establish the safety of cosmetic products or ingredients. 26
This self-regulatory scheme provides the cosmetics industry with
only a vague idea of determining a product or ingredient to be safe:
[The] FDA has stated that "the safety of a product can be adequately substantiated through (a) reliance on already available
toxicological test data on individual ingredients and on product
formulations that are similar in composition to the particular
cosmetic, and (b) performance of any additional toxicological and
other tests that are appropriate in light of such existing data
and information."27
19. Inspection ofCosmetics, U.S. FOOD &DRUGADMIN., http://www.fda.gov/Cosmetics
/ComplianceEnforcement/ucm136455.htm [https://perma.cc/7Q5A-J8ED].
20. See 21 U.S.C.A. § 374 (West 2017).
21. FDA Authority over Cosmetics, supra note 7.
22. Id.
23. Guidance & Regulation, U.S. FOOD &DRUG ADMIN., http://www.fda.gov/Cosmetics
/GuidanceRegulation/default.htm [https://perma.cc/BK7Z-USPX].
24. Id.
25. Id.
26. FDA Authority over Cosmetics, supra note 7.
27. Id. (citation omitted).
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While the FDA also conducts its own cosmetics safety research, action is only taken against an allegedly unsafe product after that
product has been introduced on the market and may have affected
consumers. 28

B. Federal Food, Drug, and Cosmetic Act Legislative History
Delving into the legislative history of the FD&C Act reveals little
information on the thinking behind creating such comprehensive
regulation for food and drugs, and comparatively so little for cosmetics.29 Congress passed the FD&C Act in 1938 and for the first time
created consumer protection over medical devices and cosmetics. 30
Upon its consideration by the seventy-fourth Congress in 1935, President Roosevelt said ofthe then-bill:
[i]t is time to make practical improvements. A measure is needed
which will extend the controls formerly applicable only to labels
to advertising also; which will extend protectwn to the trade in
cosmetics; which will provide for a cooperative method of setting
standards and for a system of inspection and enforcement to
reassure consumers grown hesitant and doubtful; and which will
provide for a necessary flexibility in administration as products
and conditions change. 31

Roosevelt specifically called for the protection of the cosmetics industry in his special statement to Congress, yet only a few provisions
were ultimately included. 32
The major issues surrounding the bill made no mention of the
discrepancies in the depth and breadth ofregulation between cosmetics and food and drugs. 33 These issues dealt primarily with the FDA's
power to make multiple product seizures; which agency should have
jurisdiction over food, drug, and cosmetic advertising; and judicial review of regulations made by the Secretary of Agriculture. 34 Over the
next few years the bill was debated, and in 1937, the definition of
28. See Science & Research, U.S. FOOD &DRUGADMIN., http://www.fda.gov/Cosmetics
/ScienceResearch/default.htm [https://perma.cdN9Z7-2UD2] [hereinafter Science and
Research].
29. See generally Cavers, supra note 13, at 2-5.
30. Summary of NDA Approvals & Receipts, 1938 to the present, U.S. Foon & DRUG
AD:MlN., http:/lwww.fda.gov/AboutFDAIWhatWeDo/History/ProductRegulation/Sum.m.ary
ofNDAApprovalsReceipts1938tothepresent/default.htm [https://perma.cc14AS9-TU58].
31. Cavers, supra note 13, at 12-13 (emphasis added) (citation omitted).
32. 21 U.S.C.A §§ 361-63 (West 1993); Cavers, supra note 13, at 12-13.
33. See Cavers, supra note 13, at 13-15.
34. Id.
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"cosmetic'' was added. 35 The bill eventually passed in both the House
ofRepresentatives and the Senate, and President Roosevelt signed
it into law in June of 1938. 36 Since its passage, the Act has largely
remained the same with regard to cosmetics; a fourth section originally in the cosmetics subchapter, which directed the Secretary to
promulgate regulations for the listing of coal tar coloring in cosmetics, was repealed in 1960.37
The legislative history of the FD&C Act offers little insight into
the reasoning for the relatively short list of cosmetics regulations. 38
Perhaps there were simply fewer cosmetic products in the 1930s, or
cosmetic products were not that commonplace. Regardless of the
cosmetics statistics of the years leading up to the passage of the Act,
in the past eighty years, the cosmetics industry has grown significantly as new ingredients and products have been developed and
have become more widely used. 39 The presence of such relatively extensive regulations on food and drugs in the FD&C Act still begs the
question ofwhy the same level of protection is not afforded to cosmetics, given their own health and safety implications. 40

II. COSMETICS AND THEIR CORE USERS: WOMEN
A. Defining "Cosmetic" and Analyzing Use
The United States cosmetics industry boasts an annual revenue
of over sixty billion dollars. 41 The United States was considered the
most valuable beauty and personal care market globally in 2016,
leading North America to make up almost a quarter of the cosmetic
market worldwide. 42 The United States cosmetics industry employs
over 63,000 people, and the industry's gross product is about $14
billion.43 Before breaking down the statistics further to determine
the industry's main consumer, it is imperative to understand the
definition of "cosmetic" under the FD&C Act:
35. Id. at 16-18.
36. Id. at 21-22.
37. 21 U .S.C.A. § 364 (repealed 1960). This topic is now covered in a separate general
authority provision encompassing cosmetics as well as food, drugs, and devices. See 21
U.S.C.A. § 379e (West 2012).
38. See 21 U.S.C.A. §§ 361--63; see generally Cavers, supra note 13.
39. See Important Cosmetic Industry Developments in the United States, COSM. INFO.,
http://www .cosmeticsinfo.org/cosmetics-developments [https:/lperma.cc/K5XP-S4TL].
40. See§§ 351-60fff-7, 361-63; see also§§ 341-501-1.
41. Statistics & Facts on the U.S. Cosmetics and Makeup Industry, STATISTA, http://
www.statista.com/topics/1008/cosmetics-industry [https://perma.cc/F45L-6C6W] [hereinafter Statistics & Facts].
42. Id.
43. Id.
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The term "cosmetic" means (1) articles intended to be rubbed,
poured, sprinkled, or sprayed on, introduced into, or otherwise
applied to the human body or any part thereof for cleansing,
beautifying, promoting attractiveness, or altering the appearance, and (2) articles intended for use as a component of any
such articles; except that such term shall not include soap. 44

Products that fall into this definition include, among many others,
such items as skin moisturizers, perfumes, lipsticks, and hair colors,
as well as individual components of a cosmetic product. 45 Some
products that would otherwise be included in this definition are defined elsewhere in the FD&C Act as a drug, device, or dietary supplement, 46 or outside of the FDA's jurisdiction altogether, as it is the
case with soap. 47
Returning to the statistics, analyzing specific product categories
sheds more light on who is actually consuming cosmetics.48 Haircare
products represent the largest part-twenty-four percent-of the
United States beauty industry. 49 Foundation sales reach over $980
million. 50 The leading cosmetic brand is Neutrogena, and their top
product is their makeup remover. 5 1 Revlon's "Beyond Natural" false
eyelashes alone account for $3.4 million in sales. 52 Each of these
statistics seems to represent popular products among not just consumers, but women specifically.53
Thirty-five percent of women use one to two cosmetic products
daily, with seventeen percent using three to four. 54 Fifty-four percent
of men, on the other hand, will not use a single cosmetic product on
a given day. 55 Women also reportedly spend more just because they
are women, often as a result of sexual prejudice in the market.56 A
study observing women across the United States found companies
charging "an unjustified markup for products marketed towards
females .... [and] on average women pay $151 billion in extra fees
and markups that men don't have to pay."57
44. 21 U.S.C.A § 321(i) (West 2016).
45. FDA Authority over Cosmetics, supra note 7.
46. ld.
47. Soap: FAQs, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/Cosmetics/Products
Ingredients/Productslucmll5449.htm [https://penna.cc/E5L8-GBL8].
48. See Statistics & Facts, supra note 41.
49. ld.
50. ld.
51. ld.
52. Id.
53. Id.
54. Adams, supra note 1.
55. ld.
56. ld.
57. ld.
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Specific statistics and research tend to support the data's conclusion that women consume cosmetic products more than men
overall. 58 A study conducted by the Centers for Disease Control and
Prevention (CDC) in 2000 found that a wide variety of cosmetic
products contained phthalates, which were largely not labeled in the
products' ingredient lists. 59 The CDC researchers discovered widespread exposure throughout the population-with adult women showing higher levels of phthalate metabolites from the use of personal
care products. 60 Moreover, research has shown a significant relationship between phthalate levels in a pregnant woman's body and
subsequent adverse effects on male reproductive development.61
Further, African-American women spend eighty percent more
per capita on cosmetic products than any other ethnic group, mainly
on haircare products such as relaxers. 62 It appears evident that
women, who tend to have longer hair than men, would be more likely
to use such products for styling or simply easier maintenance. 63
Even products that are more gender-neutral on their face show
a discrepancy in use between women and men. 64 A CDC study from
2013 showed that sunscreen, used to mitigate ultraviolet radiation
exposure and help prevent skin cancer, is used by women double the
amount when compared to men's usage.65 Over twenty-nine percent
of women said that they regularly use sunscreen on their face and
exposed skin, whereas only fourteen percent of men reported the
same.66 More women admitted to using sunscreen regularly only on
their face (about forty-three percent) versus on other exposed skin
(thirty-four percent).67 In men, these numbers were approximately
eighteen and twenty percent, respectively.68
58. Rajiv Shah & Kelly E . Taylor, Concealing Danger: How the Regulation of Cosmetics in the United States Puts Consumers at Risk, 23 FORDHAM ENVrL. L. REV_ 203,
210 (2012).
59. ld.
60. ld.
61. ld.
62. ld. at 212.
63. Merrill Fabry, Now You Krww: How Did Long Hair Become a Thing for Women?,
TIME (June 16, 20 16), http:l/time.com/4348252/history-long-hair [https://perma.cd273J
-KNA9].
64. See Study: Most Americans Don't Use Sunscreen, AM.ACAD. DERMATOLOGY (May 19,
2015), http://www.aadorg/media/newsreleaseslstudy-most-americans-don-t-use-sunscreen
[https://perma.cc/P8RY-4XQT] [hereinafter Study: Most Americans].
65. Id. Although sunscreen is actually defined as a drug under the FD&C Act, this
still offers proof that cosmetics (and products like sunscreen that would otherwise fit the
definition of"cosmetic" in the absence of their own specific provisions elsewhere in the
FD&C Act) are used by more women than men. See 21 U.S.C.A. § 360fff (West 2014).
66. Study: Most Americans, supra note 64.
67. ld.
68. ld.
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"Women may be more likely to use sunscreen on the face because of the anti-aging benefits, or because of the many cosmetic
products on the market that contain sunscreen."69 In further support
of this notion, the study also discovered that men (at almost forty-four
percent) were more likely than women (at twenty-seven percent) to
never use sunscreen on their face, and at similar percentages with
regard to other exposed skin. 70 Despite women's and men's respective reasons for sunscreen use or non-use, this study shows that
even products marketed to the general population (as opposed to
just women), for something gender-nonspecific like skin cancer prevention, are still more likely to be used by women. 71
Looking back to the FD&C Act, food and drug consumption and
usage certainly seem more equally spread amongst the genders: both
women and men consume food and use drug products and medical
devices. 72 It is true that some drugs are specifically produced for use
by only one gender (e.g., birth control); however, the outstanding difference between these gender-specific drugs and cosmetic products
is that such drugs are regulated under the FD&C Act, while cosmetics are not.

B. Cosmetics Affect Women More Than They Affect Men
Cosmetics usage has the potential to affect women (adversely, as
well as beneficially) on a larger scale than men. Health concerns may
arise primarily because cosmetic products often wind up ingested or
absorbed into the body. 73 Perhaps the most obvious example of this
is lipstick, trace amounts of which undoubtedly get inadvertently
ingested when the wearer eats, drinks, or licks her lips-the average woman is said to "eat" one to three tubes of lipstick per year,
equating to a shocking four to nine pounds in her lifetime. 74 Tracing
the history of lipstick helps to shed some light on its overall lack of
regulation, as well as its potential impact. 75
At the beginning of the twentieth century, lipstick in America
began to not only symbolize femininity, but also female emancipation,
as suffragettes endorsed the product. 76 American women would
69. Id. (citation omitted).
70. Id.
71. Id.
72. See Tammy Worth, Drugs That Work Directly in Women and Men, EVERYDAY
HEALTH (Feb. 19, 2015), http://www.everydayhealth.com/news/drugs-work-differently
-woman-than-man [https:/lperma.cc/D26P-WSYF] .
73. Sarah E. Schaffer, Reading Our Lips: The History ofLipstick Regulation in Western
Seats of Power, 62 FOOD DRUG L.J. 165, 222 (2007).
74. Id.
75. Id. at 165.
76. Id. at 176.
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publicly apply their lipstick, often in a noticeable red hue, with the
intent of appalling men and reclaiming the product as one of female
rebellion. 77 Lipsticks first appeared in their modern tubes in 1915,
making them more readily available, but neither federal nor state
safety laws examined issues with lipstick preservation or their continued use. 78 Despite the absence of cosmetics regulation under the
Pure Food and Drugs Act of 1906 (the predecessor to the FD&C Act),
some states considered limiting lipstick's use, though not for the
reasons one would hope79 :
New York's Board of Health considered banning lipstick out of
concern that it might poison the men who kissed women wearing
it. A bill introduced in the Kansas legislature's 1915 session would
have made it a misdemeanor for any woman under age 44 to wear
cosmetics if "for the purpose of creating a false impression."80

These sexist proposals did little to address the safety implications
of women's use oflipstick, but were instead concerned only with how
such use would affect men. 81
The passage of the FD&C Act in 1938 opened the door for cosmetics regulation in its grant of jurisdiction to the FDA. 82 The Act's
limitations on poisonous or deleterious substances, as well as on
false or misleading claims, allowed progress to be made in the aftermath of its enactment, and prompted some state regulation as
well.83 Further regulations involving labeling and color additives
were legislated over the next several decades. 84 The FDA attempted
to regulate lipstick itself as a color additive, which would require
FDA pre-approval before sale, but the Second Circuit Court of Appeals struck this down as exceeding the FDA's statutory authority. 85
Self-regulation has ruled since the late twentieth century, with
the FDA believing cosmetics to be of the lowest concern in terms of
being hazardous. 86 Concerns about shortcomings of industry selfregulation were not addressed by the FDA, it was only addressed in
some state legislatures.87 During the 1990s, the FDA grappled with
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.

Id.
Id. at 177.
Schaffer, supra note 73, at 177.
Id. at 177-78 (citation omitted).
Id.
Id. at 182.
Id. at 182-85.
Id. at 189-91.
Schaffer, supra note 73, at 193-94.
Id. at 203-04.
Id. at 204.
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(a) conflicting views of allowing the cosmetics industry to self-regulate
based on cosmetics' low risk, and (b) ending self-regulation based on
industry reporting problems--the cosmetics industry had only been
reporting problems at the rate of one in every fifty reports. 88 Today,
the FDA can still only regulate pre-market with regard to adulterated or misbranded cosmetics and can test and analyze products
post-market to address safety concerns. 89
In December 2016, the FDA issued non-binding draft guidance
on the recommended maximum level oflead in cosmetic lip products
and externally applied cosmetics. 90 This guidance stemmed from the
2007 Campaign for Safe Cosmetics' (CSC) finding of lead in a small
selection of lipsticks on the market.91 In response, the FDA examined lead levels not only in lipsticks, but in other externally applied
cosmetics such as mascara, eye shadows, lotions, and powders. 92 The
results showed that more than ninety-nine percent of the cosmetics
surveyed had less than ten parts per million (ppm) lead. 93 The FDA
concluded that because it seemed that the vast majority of manufacturers could keep lead levels in their products at ten ppm or below,
this number should be the threshold amount. 94 They further determined that up to ten ppm lead in cosmetic products does not pose a
health risk to the (specified as female) user:
Exposure to lead from lipstick is mainly by swallowing, such as
after a consumer licks her lips, so we used the same approach for
cosmetic lip products that we use to estimate exposure to lead
from food. We determined that exposure to 10 ppm lead from
incidental ingestion of cosmetic lip products is very small and
cannot be measured in routine blood testing. 96

Exposure to lead from other cosmetics is by absorption through the
skin, but the amount absorbed is very small.96 This means that
exposure to lead from a product such as eyeshadow or body lotion is
88. Id. at 211.
89. FDA Authority over Cosmetics, supra note 7.
90. U.S. FOOD & DRUG ADMIN., DRAFT GUIDANCE FOR INDUSTRY: LEAD IN COSMETIC LIP
PRODUCTS AND EXTERNALLY APPLIED COSMETICS: RECOMMENDED MAxiMUM LEVEL (Dec.
2016), http:/fwww.fda.gov/Cosmetics/GuidanceRegulation/GuidanceDocumentslucm452623
.htm [https://perma.cc/UN38-N79T] [hereinafter DRAFT GUIDANCE FOR INDUSTRY].
91. Limiting Lead in Lipstick and Other Cosmetics, U.S. FOOD & DRUG ADMIN.
(Feb. 22, 2018), http:/fwww.fda.gov/Cosmetics/Productslngredients/Producta/ucml37224
.htm [https:f/perma.cdS3JE-FNR9] [hereinafter Limiting Lead in Lipstick].
92. Id.
93. Id.
94. Id.
95. Id. (emphasis added).
96. Id.
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even lower than exposure to lead from a lipstick or other lip cosmetics; moreover, it cannot be measured in routine blood testing. 97
Unaddressed by the FDA, however, is whether women using a
combination ofmany externally applied cosmetics with a trace amount
of lead increases chances of a health risk. 98 It is also imperative to
recall that FDA guidance documents do not establish legal remedies
and merely reflect the FDA's current stance on a topic. 99
Despite health and safety concerns brought to the FDA's attention by individuals and organizations such as esc, because these
examinations in response are conducted post-market, it is inevitable
that some products fall through the cracks and continue to be sold
and used. 100 In 2004, Jessica Simpson debuted her "Dessert Beauty''
collection, which included lip glosses, lotions, and fragrances, all marketed as edible. 101 Pink and glittery Dessert Beauty advertisements
declared "It's a fragrance. It's a flavor." and "Be fabulously :flavored." 102
Although it is the Federal Trade Commission (FTC), not the FDA,
that has jurisdiction over both food and cosmetics advertising, 103 no
lawsuit was filed alleging adulteration or misbranding as either a
food or cosmetic product, nor was a health and safety concern brought
to the FDA. 104 The line was discontinued years later following intellectual property lawsuits alleging patent and copyright infringements,
but one must wonder how safe it really was for female customers to
"eat" these products. 105
Beyond the safety fears of ingesting lipstick, a myriad of cosmetics health and safety concerns exist with the increased potential to
affect women as cosmetics' core consumers. For instance, Keratin
hair-straightening treatments can contain formaldehyde, a known
carcinogen and eye, nose, throat, skin, and lung irritant. 106 These
97. Limiting Lead in Lipstick, supra note 91.
98. Seeid.
99. DRAFT GUIDANCE FOR INDUSTRY, supra note 90.
100. FDA Authority over Cosmetics, supra note 7.
101. Tori Telfer, Whatever Happened to Jessica Simpson~ Dessert Beauty Line? A Bunch
Of Lawsuits, Apparently, BUSTLE (Aug. 28, 2014), https:/lwww.bustle.com/articles/37714
-whatever-happened-to-jessica-si.mpsons-dessert-beauty-line-a-bunch-of-lawsuits-appar
ently [https://perma.cd95HP-S6JT].
102. Dessert Perfume-Jessica Simpson, CELEBRITY SENSATION, http://www.celebrity
scentsation.com/celebrity-perfumes/musicians/jessica-simpson/dessert-perfume
[https://perma.cdC466-JNME].
103. Advertising FAQ'S: A Guide for Small Business, F.T.C., http://www.ftc.gov/tips
-advicelbusiness-center/guidance/advertising-faqs-guide-small-business [https://perma
.cc!KH7G-3CCJ].
104. Telfer, supra note 101.
105. ld.
106. Anastasia De Paz, Note, The Cosmetic Regime Needs a Makeover: Advocating to
Empower the FDA Through the Safe Cosmetics Act of 2011, 31 TEMP. J. SCI. TECH. &
ENVTL. L . 337, 340 (2012).
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treatments have been found to contain formaldehyde even when
labeled formaldehyde-free, but it is not illegal under the FD&C Act
to manufacture and sell formaldehyde-containing cosmetics. 107 Industry self-regulation can also be misleading, as products are deemed
safe only in accordance with short-term side effect studies that do
not include data regarding continued product use over a long or
specific developmental period of time (e.g., puberty). 108
Continued cosmetics usage logically results in continued ingestion
and/or absorption of their ingredients:
Cosmetics that are applied to the skin will be absorbed. What is
absorbed will be stored in fatty tissue. Studies show that
women's bodies store chemicals cumulatively more effectively
than men's bodies, placing women at greater risk. While exposures to an individual chemical in a single personal care product
may not cause harm, the average American woman uses 12 personal care products per day exposing her to approximately 126
unique chemicals.109

Other chemicals regularly used in cosmetic products, such as progesterone and estrogenic chemicals, are also dangerous to women,
posing harm during puberty and pregnancy and increasing the risk
for breast cancer. 110 Biological differences in combination with simply
using more cosmetic products more frequently over long periods of
time, place women at a heightened health and safety risk with very
little federal legal recourse. 111

C. Adversely Affected Women Currently Have Limited Options in
Seeking Legal Recourse Without Federal Cosmetics Regulation
Since the FDA can only take legal action over products alleged
to be adulterated or misbranded, it cannot issue a mandatory product recall or seizure upon receipt of adverse reports. 112 Furthermore,
when consumers make adverse product reports to the manufacturer,
the manufacturer is not legally required to send these or other
reports of adverse events to the FDA.m This roadblock results in
107. Id.
108. Id. at 340-41.
109. Id. at 341.
110. Id.
111. Id.
112. FDA Information for Consumers About WEN by Chaz Dean Cleansing Conditioners, U.S. FOOD & DRUG ADMIN. (Nov. 3, 2017), http://www.fda.gov/Cosmetics/Products
lngredients/Products/ucm511631.htm [https://perma.cc/VD8X-B5NT] [hereinafter FDA
Information for Consumers].
113. Id.
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class action personal injury lawsuits against the manufacturer, but
without accompanying FDA-sanctioned consequences. 114
In the case ofFriedman v. Guthy-Renker, LLC, plaintiffs brought
a class action suit against WEN by Chaz Dean, Inc., the brand, and
Guthy-Renker, the manufacturer, alleging hair loss and scalp irritation resulting from the use of WEN haircare products. 115 All but one
claim (for breach of warranty) were brought under California law, 116
absent the ability to seek an injunction from the FDA to stop the
production or sale of this product. 117 Defendants continued to stand
behind the safety of their products, as WEN "has not been proven to
cause hair loss to consumers, nor has it been legally determined
that any advertising of the [p]roducts was false or misleading." 118
Despite the defendants' assertions and to avoid the costs of litigation, the case resulted in a settlement, which was granted preliminary approval by the United States District Court for the Central
District of California in 2016. 119 An order granting final approval
and a final settlement judgment were granted in August 2017, with
several subsequent appeals filed a month later. 120
Even if these affected women ultimately receive a settlement
payment, their suffering was likely much more distressing than if the
victims were men. 121 "Hair loss in women can be absolutely devastating for the sufferer's self image and emotional well being. Unfortunately, society has forced women to suffer in silence. It is considered
far more acceptable for men to go through the same hair loss process."122 Societal norms have created an environment in which female
hair loss results in psychological damage, that can be so emotionally
taxing in a way that may eventually affect physical health. 123
Whether physical, mental, or both-health issues arising from the
use of cosmetic products can and do affect women in a more significant way than they affect men. Women, as the primary consumers
of cosmetic products, ultimately use these products at a greater rate
114. See, e.g., WEN HAIR CARE CLASS ACTION OFFICIAL SETTLEMENT WEBSITE, http://
www.wenclassaettlement.com [https://perma.cd85VP-LXLM] [hereinafter WENHAm CARE].
115. Friedman v. Guthy-Ren.ker, LLC, No. 2:14-cv-06009-0DW(AGRx), 2016 U.S. Dist.
LEXIS 149900, at *2--3 (C.D. Cal. Oct. 28, 2016).
116. Id. at *4.
117. FDA Information for Consumers, supra note 112.
118. WEN HAIR CARE, supra note 114.
119. Friedman, 2016 U.S. Dist. LEXIS 149900, at *3, *29.
120. News, WEN HAIR CARE CLASS ACTION, http://www.wenclasssettlement.com/News
[https://perma.cdQT2A-FYBS].
121. See generally Women's Hair Loss: Introduction, AM. HAIR Loss AsS'N, http://
www.americanhairloss.org/women_hair_loss/introduction.asp [https://perma.cc/X9DP
-ZEHM] [hereinafter Women's Hair Loss].
122. Id.
123. Id.
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than men. 124 A greater percentage of women than men report regularly using even gender-neutral products like sunscreen. 125 On the
other end ofthe product spectrum, lipstick, a socially female-specific
cosmetic, gets inadvertently ingested but has no federal ingredient
requirements or limitations. 126 Other products pose health concerns
to women simply due to biological differences, such as women's predisposition ofhigher chemical retention in fatty tissue. 127 Still, more
products may cause adverse effects that are more emotionally devastating to women than they would be to men, which, in turn, can also
affect their physical health. 128 Overall, cosmetics affect women, and
so does the lack of federal cosmetics regulation under the FD&C Act.
III. THE LACK OF FD&C ACT REGULATION OVER COSMETICS
HAS A DISPARATE IMPACT ON WOMEN
The ways in which cosmetics affect women specifically cause the
FD&C Act to have a disparate impact on women as a class. "Disparate impact'' is defined as "[a]pparently neutral behavior that has
a discriminatory e:ffect." 129 A disparate impact claim has no requisite
intent and may be established even if the law is facially nondiscriminatory.130 The FD&C Act is clearly neutral on its face; there are no
provisions which apply or grant protections to only males or only
females. 131 But due to the overall lack of cosmetics regulation under
the Act, and for the concerns set forth in Part II of this Note, the Act
effectually has a disparate impact on women. 1s2
Equal protection is not a novel issue for the FDA.m In the
clinical trial context, FDA guidelines from 1977 "recommended the
exclusion of women of childbearing potential from early phase drug
trials." 1s4Over a decade later, the FDA modified this guidance with
124. See Exposures Add Up-Survey Results, EWG's SKIN DEEP COSM. DATABASE,
http:/lwww.ewg.org/skindeep/2004/06/15/exposures-add-up-survey-results/#.W4xRri2
ZPBJ [https://perma.cc/JJBV-7Q7F].
125. Study: Most Americans, supra note 64.
126. See Limiting Lead in Lipstick, supra note 91.
127. De Paz, supra note 106, at 341.
128. See, e.g., Women's Hair Loss, supra note 121.
129. Disparate Impact, THE WOLTERS Kl..UWER BOUVIER LAW DICTIONARY DESK EDITION (20 12).
130. Id.
131. See 21 U.S.C. §§ 301-399h (2012).
132. See discussion supra Part II.
133. See WOMEN AND HEALTH RESEARCH: ETHICAL AND LEGAL ISSUES OF INCLUDING
WOMEN IN CLINICAL STUDIES 146 (Anna C. Mastroianni et al. eds., 1994), https:/lwww
.ncbi.nlm.nih.gov/pubmed/25144026 [https://perma.cc/TGE7-PPVZ] [hereinafter WOMEN
AND HEALTH RESEARCH].
134. Id. at 147.
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the 1993 Guideline for the Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs. 135 This recommended that
the subjects in a clinical study reflect the actual population that will
receive the drug once it is on the market. 136 Although this new guideline advocated, but did not require, that women participate in the
early stages of drug trials, it created an expectation of identifying
whether a gender difference exists in response to a drug, and, if so,
the basis of that gender difference. 137 The inclusion of women in
clinical studies would help to indicate post-market effects on women
that were never before evaluated pre-market, such as response to a
drug based on the varying hormone levels of the menstrual cycle. 138
Additionally, female inclusion would open the door to recognizing
the need for further testing on specific subsets of the population to
determine the drug's safety and efficacy. 139
The Supreme Court has not decided an equal protection challenge to a demographic restriction in clinical trials, but "legal experts maintain that research policies that result in the exclusion of
women as a class, whether on their face (with explicit exclusionary
language) or in effect (because they result in disproportionate participation of men and women), may be found to contradict the equal
protection clause." 140 The Supreme Court's holding that the equal
protection clause ofthe Constitution restricts the government's (and
its agencies') right to treat similarly situated people differently
supports this theory. 141
Critically, a law being unconstitutional and a law having a
disparate impact are not the same. 142 The Supreme Court in Feeney
held that a neutral law may have a disproportionate, adverse effect
on a minority but requires a discriminatory intent to be unconstitutional.143 The Court further held that "[c]lassifications based upon
gender, not unlike those based upon race, have traditionally been
the touchstone for pervasive and often subtle discrimination." 144
This Note does not purport to argue that the FD&C Act and its lack
of cosmetics regulation are unconstitutional because its drafters
intended to adversely discriminate against women; the FD&C Act
135.
136.
137.
138.
139.
140.
141.
142.
143.
144.

Id. at 139.
Id. at 139--40.
Id. at 140.
Id.
WOMEN AND HEALTH RESEARCH, supra note 133, at 140.
Id. at 146 (emphasis omitted).
See id.
Pers. Adm'r of Mass. v. Feeney, 442 U.S. 256,272 (1979).
Id.
Id. at 273.
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instead has a disparate impact on women in its application that
must be remedied.
IV. THE COSMETICS INDUSTRy'S CURRENT SELF-REGULATION
REGIME DOES NOT CURE THIS DISPARATE IMPACT; THUS,
ADDITIONAL FEDERAL REGULATION Is NEEDED

One could argue that the cosmetics industry's current selfregulatory scheme does not require federal intervention because the
FDA's current authority is sufficient and has worked since the FD&C
Act's enactment. 145 Although the industry is ultimately responsible
for product safety, the FDA can advise by issuing guidance documents
and monitor once a product has been flagged as unsafe. 146 In regards
to cosmetic testing, the FDA has consistently advised the industry
to use whatever testing necessary to ensure product safety. 147 The
FDA also monitors the conduction of product recalls, and may even
request a recall if a company refuses to remove dangerous products
from the market. 148 However, unlike in the past, much of the industry seems to agree that this is not enough. 149 A study conducted from
2004 to 2016 found that consumers and healthcare providers reported an average of 400 cosmetics-attributed adverse events per
year. 15°Consumer complaints more than doubled from 2015 to 2016
due to the WEN haircare product events. 151 Most notably, the number of cosmetics-related adverse events reported to the FDA was
considerably lower than those reported for drugs and medical devices. 152 Cosmetics manufacturers are not required to disclose to the
FDA any complaints they receive, which likely explains this discrepancy.153 "[U]nder existing law, the [FDA] could take action against
[a] company only if it could prove a product had been mislabeled or
contaminated. If the product turns out to be dangerous but legal,
the government has no recourse." 154
145. See, e.g., Pepper Hamilton ILP, Regulation of Cosmetics: Is Increased FDA Oversight on the Horizon?, LEXOLOGY(Nov. 28, 2017), http://www.lexology.com/library/detail
.aspx?g=4aac2d85-479c-4837-837b-4bd15e0dc584 [https://perma.cc/CQK8-HJCW].
146. FDA Authority over Cosmetics, supra note 7.
147. Id.
148. Id.
149. See, e.g., Pepper Hamilton LLP, supra note 145.
150. Id.
151. Id.
152. Id.
153. Id.
154. Eric Lipton & Rachel Abrams, Their Hair Fell Out. Should the F.D.A. Have the
Power to Act?, N.Y. TIMES (Aug. 15, 2016), http://www.nytimes.com/2016/08/16/us/politics
/cosmetics-industry-congress-regulation-wen.html [https://perma.cc/KA5G-VLCN].
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This lack of oversight in effect puts the burden on the consumer
to investigate which ingredients may be harmful to her. 155 ''It is a situation in which the old adage 'let the buyer beware' truly applies." 156
Furthermore, many effects of certain ingredients on human-namely,
women's-health were not known in 1938; thus, the law as it stands
does not reflect the past eighty years' breadth of know ledge. 157 Three
notable pieces of legislation-the Personal Care Products Safety
Act, the Safe Cosmetics Modernization Act, and the FDA Cosmetic
Safety and Modernization Act of 20 17-have been introduced over
the past several years in both the House and the Senate aiming to
tackle the disparate impact on the female consumer, albeit to varying degrees. 108

A. Personal Care Products Safety Act
Introduced by Senators Dianne Feinstein and Susan Collins in
2015 and reintroduced in May 2017, the Personal Care Products
Safety Act (PCPSA) would broaden FDA authority over cosmetics in
a number ofways. 159 The bill requires the FDA to evaluate a minimum of five ingredients per year to determine their safety and appropriate use, going so far as to dictate the first five ingredients to be
analyzed: four preservatives and one color additive. 160 PCPSAoutlines
the standard of review for this requirement as "determining whether
there is 'adequate evidence to support a reasonable certainty among
competent scientists that the ingredient is not harmful."' 161
PCPSA also grants the FDA the authority to establish conditions for safe use of an ingredient, order recalls of cosmetics posing
safety risks, and conduct cosmetics safety activities funded by cosmetics companies' required fees. 162 Cosmetics facilities would have
to register with the FDA, and companies would also be required to
submit annual reports of all adverse events. 163 An express preemption provision in the bill would prohibit states from imposing regulations different from or in addition to the FDA's. 164
155. Should the FDA Crackdown on the Cosmetics Industry?, Om. FOR PLAsTIC SURGERY
(Sept.15, 2016), http://www.cpsdocs.comlblog/fda-crackdown-cosmetics-industry [https://
perma.cc/K8KL-SCK5].
156. Id.
157. Seeid.
158. See Lipton & Abrams, supra note 154; see also Pepper Hamilton LLP, supra note
145.
159. See Pepper Hamilton LLP, supra note 145.
160. Id.
161. Id. (citation omitted).
162. Id.
163. Id.
164. Id.
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Response to PCPSA has been positive from many ofthe big names
in the industry. 165 Johnson & Johnson created a webpage entitled
"Consumer Confidence Is More Than a Formula" to outline its support for PCPSA. 166 The webpage names the key features of PCPSA
to highlight the goal of"bringing peace of mind to consumers." 167 A
Johnson & Johnson lobbyist touted PCPSA as "'supported by a vast
and diverse group of people and groups who all want the same
thing-cosmetic regulations that best serve the public health and
give consumers confidence in the products and ingredients they
choose for their families.' " 168 Proctor & Gamble reiterated its support for PCPSA even after the introduction of a second cosmetics
reform bill in the Senate in October 2017. 169 Other major environmental, consumer, and health groups, including the American Cancer
Society, have also supported the bill. 170
Others, including the Independent Cosmetic Manufacturers and
Distributors (ICMAD) and cosmetics company Mary Kay, have criticized PCPSA as "overreaching'' and failing to provide a clear uniform
safety standard. 171 The beauty care trade association, to which WEN
haircare's distributor belongs, has also lobbied against PCPSA. 172
"The fight has pitted smaller independent players against the giants
of the beauty products industry, which back the proposed regulations, seeing them as an avenue toward regaining public trust, and
have the size and muscle to comply with them.'ma In response to this
backlash, the most recent version of PCPSA added a provision exempting small businesses (those averaging less than $500,000 in
gross sales over 3 years as well as home-based businesses averaging
less than $1 million) from its requirements. 174

B. Safe Cosmetics Modernization Act
In response to smaller companies' backlash against PCPSA,
Representative Pete Sessions introduced competing legislation in
165. See Lipton & Abrams, supra note 154.
166. Consumer Confidence is More Than a Formula, JOHNSON &JOHNSON, http://www
.cosmeticsreform.com/index.html [https://perma.cciZN87-ZQZU].
167. Id.
168. Lipton & Abrams, supra note 154 (citation omitted).
169. Joanne S. Hawana, A "Surprise" Cosmetic Reform Bill Appears in Congress;
Bipartisan Compromise Continues to Be Legislators' Goal, NAT'L L. REv. (Nov. 15, 2017),
http :1/www.natlawreview.com/article/surprise-cosmetic-reform-bill-appears-congress-bi
partisan-compromise-continues-to-be [https://perma.cc/FLD4-GNSP].
170. See Lipton & Abrams, supra note 154.
171. Id.
172. Id.
173. Id.
174. See Pepper Hamilton LLP, supra note 145.
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the House in late 2015, and again in early 2017. 175 The Cosmetic
Modernization Amendments, also referred to as the Safe Cosmetics
Modernization Act (SCMA), 176 establishes similar requirements to
PCPSA. 177 The key difference for PCPSA critics lies in SCMA's grant
of authority for the FDA to establish exemptions to the bill's requirements "for ... efficient and cost-effective implementation." 178
ICMAD opposes PCPSA, claiming that it would place too large
a burden on small businesses, would not provide reasonable national
uniformity, and would stifle industry innovation. 179 ICMAD instead
"strongly supports" SCMA, which asserts that it would modernize
current FDA cosmetics regulation while supporting small businesses
and innovation. 180 While PCPSA would allow the FDA to collect approximately twenty million dollars in annual fees from cosmetics
companies to help cover the cost of the mandatory safety testing on
at least five ingredients per year, SCMA does not grant the authority to order recalls or collect industry fees for safety evaluation. 181
SCMA purports to cure the issue of national uniformity by
remaining consistent with the Safe and Accurate Food Labeling Act
and the Microbead-Free Waters Act of 2015. 182 "Unlike the Personal
Care Products Safety Act, [SCMA] creates transparency in all health
and safety decisions related to cosmetics and increases consumer
protections. It does all this without overburdening small businesses
or stifling the innovation that is the lifeblood of our industry." 183

C. FDA Cosmetic Safety and Modernization Act of 2017
In October 2017, Senator Orrin Hatch introduced another piece
of federal cosmetics oversight legislation, which, like SCMA, addresses existing concerns with PCPSA. 184 This bill, known as the FDA
175. See Cosmetic Modernization Amendments of2017, H.R. 575, 115th Cong. (2017);
see also ICMAD's Statement on Support of Legislation to Modernize the FDA's Oversight
Over Cosmetics, lNDEP. COSM. MANuFACTURERS AND DISTRIBUTORS (Aug. 15, 2016), http://
icmad.org/advocacyllegi.slative-advocacy-program [https://perma.cc/Y5ZL-RZBL] [hereinafter ICMAD's Statement].
176. ICMAD's Statement, supra note 175.
177. Compare H.R. 575, 115th Cong. (2017), with Personal Care Products Safety Act,
S.ll13, 115th Cong. (2017).
178. H.R. 575, 115th Cong. § 1(b) (2017).
179. ICMAD's Statement, supra note 175.
180. Id.
181. See Lipton & Abrams, supra note 154.
182. ICMAD's Statement, supra note 175.
183. Pam Busiek, Personal Care Oversight Measure Would Hurt Small Businesses,
HILL (Sept. 22, 20 16), http;//thehill.com/blogs/congress-blog/healthcare/297068-personal
-care-oversight-measure-would-hurt-small-businesses [https://perma.cc/9WRU-SZ7M].
184. Hawana, supra note 169.
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Cosmetic Safety and Modernization Act (referred to as the "Hatch
bill"), introduces measures for the FDA to regulate cosmetic ingredients, monitor adverse reactions, and establish good manufacturing
practices. 185 Specifically, the Hatch bill gives the FDA authority to
accredit third-party organizations to determine chemical safety, and
preempts state action on cosmetic chemical ingredients once the
FDA identifies such an ingredient for review. 186
An essential difference between the Hatch bill and PCPSA is the
source of funding for the FDA's new work. 187 While PCPSA allows
the FDA to collect fees from the cosmetics industry, the Hatch bill
relies on congressional appropriations and allows for accredited third
parties to assess safety. 188 1t is unclear whether congressional appropriations would fund such third parties or if they must bear the cost
themselves; however, the third parties must not be financially affiliated with any cosmetics manufacturer or supplier. 189 The Hatch bill
thus takes the burden off the industry itself to incur regulatory costs,
but would in turn be an additional cost to the government controlled
by Congress. 190
The two Senate bills also differ with regard to their burdens of
proof for cosmetic product safety. 191 Whereas PCPSA requires the
FDA to review the safety of five chemicals per year and places the
burden on the manufacturer to establish that chemicals in their
products show reasonable certainty of no harm, the Hatch bill takes
a different approach. 192 The Hatch bill authorizes chemical safety
reviews by accredited third parties, but without any timeline or
further specifics. 193 The ultimate burden lies with the FDA to show
that a chemical is "not injurious" under usual use. 194
The Hatch bill enjoyed immediate support from the Personal
Care Products Council, 195 as well as from ICMAD. 196 Critiques from
organizations such as the Environmental Working Group (EWG)
185. Id.
186. Id.
187. Id.
188. Id.
189. Id.
190. Hawana, supra note 169.
191. Id.
192. Id.
193. Id.
194. Id.
195. Statement by Lezlee Westine, President and CEO Personal Care Products Council
on the Introduction of the FDA Cosmetic Safety and Modernization Act, PERS. CARE PRoDUCTS COUNCIL (Oct. 25, 2011), http://www.personalcarecouncil.org/newsroom/PCPC
-Statement-on-the-Introduction-of-the-FDA-Cosmetic-Safety-and-Modernization-Act
[https://perma.ccf3PB2-XN64] [hereinafter Statement by Lezlee Westine].
196. Hawana, supra note 169.
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maintained support for PCPSA, expressing concern that the Hatch
bill would be less protective of consumers and would fail to provide
funding to the FDA to support this new regulatory role. 197
EWG asserts that the Hatch bill "is full ofloopholes that would
make a broken law even worse." 198 In contrast to PCPSA, the Hatch
bill does not require (1) companies to share ingredient information
with the FDA; (2) safety substantiation records; (3) review of a specific
number of chemicals with any deadline; nor (4) disclosure of salon
product ingredients in an effort to protect salon workers who are
exposed to these products daily. 199 The Hatch bill requires reporting
of only "serious" adverse effects and does not consider temporary hair
loss to be "serious."200 Also of note, the Hatch bill would prevent states
from enacting their own cosmetics regulations once the FDA identifies a chemical for review, which would allow an administration to
preempt state action ''by simply creating a list of chemicals."201
EWG concludes that the Hatch bill is not bipartisan, is unsupported by the industry in terms of cosmetics manufacturers and health
groups and does not meet the principles laid out by the Personal
Care Products Association, the industry trade association.202 Relying
on Congress to appropriate funding does not guarantee any amount
for the Hatch bill to support itself.203 In contrast, PCPSA relies on
industry funding, while still exempting smaller cosmetics companies, which would provide greater assurance that the FDA would
have the resources to comply. 204

D. The Personal Care Products Safety Act Has the Greatest Potential
to Address the Current Disparate Impact on Women and Should
Thus Become the New FDA Cosmetics Regulatory Regime
Though each piece of proposed legislation arguably contains
pros and cons, it is clear that some form of federal cosmetics regulation must be enacted. The Personal Care Products Council in its
support for the Hatch bill stated:
197. Id.
198. Melanie Benesh & Scott Faber, Beauty and the Beast: Fix Broken Cosmetics Law
with Real Reform, Not Loopholes, EWG (Oct. 27, 2017), http://www.ewg.org/enviroblog
/2017110/fix-broken-cosmetics-law-real-reform-not-loopholea#.WoDhF5M-cWp [https:/1
perma.cc/6LX4-SF6K].
199. Id.
200. Id.
201. Id.
202. Id.
203. Id.
204. See Benesh & Faber, supra note 198.

2018]

MAKEUP CALL

243

[W]e support modernizing cosmetics regulation to ensure FDA
has the appropriate resources and administrative authority to
continue to oversee our products. We also believe strongly that
well-crafted, science-based reforms will enhance our industry's
ability to innovate and further strengthen consumer confidence
in the products they trust and enjoy every day. 205

They further emphasized that they "urge Congress to move swiftly
to pass cosmetics legislation this year." 206 EWG, a staunch opponent
of the Hatch bill and proponent of PCPSA, noted that the current
regime is "badly broken" and should be modernized after eighty
years offailure. 207 Regardless of which bill they support, the overall
consensus among those in the cosmetics industry favors an update
to the FD&C Act in the name of consumer protection. 208
Overall, however, PCPSA appears to be the best equipped to
tackle the disparate impact women face with regard to cosmetics
regulation, or its current lack thereof. 209 For the foregoing reasons
enumerated by EWG, PCPSA has a strong advantage over the Hatch
bill in ultimately providing consumer assurance and protection. 210
Returning to the WEN haircare events to illustrate an example,
the Hatch bill only requires the reporting of"serious" adverse effects,
which do not include temporary hair loss. 211 The women affected by
the WEN hair products would still have no legal recourse under the
Hatch bill separate from suing the manufacturer directly-the Hatch
bill creates no additional protection. 212
Similarly, the House SCMA bill "would require beauty care companies to notify the F.D.A. of'serious cosmetic adverse events,' but it
would not grant the agency the power to order a recall."213 It would
also "broadly and retroactively'' preempt any state laws with higher
standards, thus eliminating any additional state-specific protection.214
In contrast, PCPSA requires cosmetic manufacturers to report to
the FDA any serious adverse effects within fifteen days ofbeing made
aware, as well as to provide annual reports of all adverse effects. 215
205. Statement by Lezlee Westine, supra note 195.
206. Id.
207. Benesh & Faber, supra note 198.
208. See Lipton & Abrams, supra note 154; Statement by Lezlee Westine, supra note
195; see, e.g., Benesh & Faber, supra note 198.
209. See Benesh & Faber, supra note 198.
210. Id.
211. Id.
212. Seeid.
213. Lipton & Abrams, supra note 154 (citation omitted).
214. Id.
215. See Benesh & Faber, supra note 198.
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Even ifPCPSA, like the Hatch bill, did not define cosmetic-productuse-induced hair loss as "serious," the FDA would still be notified of
such events within a year. 216 The affected women would therefore
have additional remedies in the form of an FDA-authorized recall
and government action against Guthy-Renker for failing to substantiate the safety of the WEN products. 217
PCPSA also addresses the issue of cosmetics that do not produce
adverse effects per se but can be unhealthy to use long-term, such as
inadvertently ingesting lead-containing lipstick.218 PCPSA "requires
companies to share ingredient information with the FDA so that the
agency's scientists can better evaluate how consumers are exposed to
cosmetics chemicals."219 It also requires companies to actively substantiate the safety of their cosmetic products and maintain such
records, allowing FDA access. 220 These active requirements on companies would not only help to avoid post-market adverse events, but
also prevent consumer use of products that only cause health issues
over time or under certain circumstances such as pregnancy. 221
The Hatch bill lacks such ingredient information sharing and
safety substantiation requirements.222 Without these provisions,
companies are more likely to continue operating as they do under
the self-regulatory system, since the FDA would not require additional safety information to be submitted from them. 223 The Hatch
bill attempts to establish good manufacturing practices, but prohibits the FDA "from imposing standards for which there is no current
and generally available analytical methodology," thus limiting its
own scope. 224 SCMA, like the Hatch bill, also allows for third party
safety substantiation for certain cosmetic ingredients, leaving the
door open for the industry to maintain its current routine. 226
Perhaps the most compelling argument in favor ofPCPSA is its
source of funding. 226 PCPSA would collect approximately twenty
million dollars annually from industry-user fees. 227 This funding
would allow the FDA to cover the costs ofthe bill's requisite testing
216. Seeid.
217. See Benesh & Faber, supra note 198; Pepper Hamilton LLP, supra note 145.
218. See Benesh & Faber, supra note 198.
219. Id.
220. Id.
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224. See Hawana, supra note 169.
225. CosmeticModernizationA.mendmentsof2017, H.R. 575, 115th Cong. § 609(a}-(b)
(2017).
226. See Benesh & Faber, supra note 198.
227. See Hawana, supra note 169; see also Lipton & Abrams, supra note 154.
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of five cosmetics per year, which in turn would help manufacturers
in the long run by effectually performing safety substantiations of
common cosmetic ingredients for them. 228 The industry funding
would also subsidize necessary resources for the FDA's affirmative
power under PCPSA to act in response to adverse events. 229
PCPSA addresses concerns that many of its opponents have
expressed with regard to forcing small businesses to pay fees they
cannot afford.230 It protects smaller cosmetics companies from having
to pay these fees when their revenues are below a certain amount. 231
It also allows a simpler registration process for companies with sales
below two million dollars, unless they manufacture products deemed
to be "high-risk."232 Though critics may see this as an industry burden,
this high-risk exemption maintains PCPSA's ultimate goal of effectuating consumer safety in the cosmetics market. 233
In short, PCPSA, by mandating industry funding, ensures compliance with and performance of its provisions.234 The absence of
mandatory industry fees in both the Hatch bill and SCMA do not
allot a clear amount to the FDA to carry out their respective provisions. 235 The Hatch bill's reliance on congressional appropriation
allows legislators to allocate FDA resources on a whim, tolerating
potential partisan implications where funding depends on which
political party is in power. 236 To remedy the disparate impact that
has affected women for at least the past eighty years, the new law
should require consistency and neutrality in its resources and
application. Of the current proposed legislation, PCPSA is the best
prepared to finally eliminate this bias.
CONCLUSION

Cosmetics are barely regulated under the FD&C Act when compared to the Act's regulations governing food and drugs. 237 Three
cosmetic-specific provisions cover adulteration and misbranding, but
provide no consumer relief allowing the FDA to regulate cosmetics
pre-market via approval or notification mechanisms, similar to those
228.
229.
230.
231.
232.
233.
234.
235.
236.
237.
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in place for certain food and drug products. 238 Nothing in the FD&C
Act's legislative history explains this discrepancy, leaving cosmetics
regulated today as they were eighty years ago. 239
As countless statistics demonstrate, women are more likely
than men to purchase and use, and thus bear any potential side
effects from, cosmetic products.240 Cosmetics wind up inadvertently
ingested and absorbed into the body without mandated pre-market
safety testing. 241 Post-market, once an adverse effect has occurred,
a consumer can report it to the manufacturer, but there is no guarantee that information will be passed on to the FDA.242 Even if it is,
the FDA does not currently have jurisdiction to initiate a response
and can only issue industry guidance that is not legally binding. 243
The lack of cosmetics regulation in the FD&C Act, therefore,
has a disparate impact on women, leaving them to rely on the cosmetic industry's self-regulatory scheme and hope that the products
they are using truly are safe. 244 A law with an existing disparate
impact minus such intent, does not result in unconstitutionality, but
simply a disproportionate effect in its application. Because women
use oosmetic products to a much greater degree than men, the FD&C
Act has a disparate impact on women that must be addressed. 246
Despite the cosmetic industry's long history of self-regulation
in the absence of federal regulations, this disparate impact continues to exist and requires amendments to the cosmetics subchapter
of the FD&C Act to prevent unsafe products from entering the market
without approval by, or at least notice to, the FDA.246 The Personal
Care Products Safety Act and the FDA Cosmetic Safety and Modernization Act in the Senate, and the Safe Cosmetics Modernization
Act in the House demonstrate Congress's recent efforts and intent
to finally impose federal cosmetics regulations.247 Each bill has garnered its own support and criticisms from different industry players,
but there is a noticeable absence of a complete anti-federal regulation stance.248
238.
1993).
239.
240.
241.
242.
243.
244.
245.
246.
247.
248.

Compare 21 U.S.C.A §§ 361--63 (West 1993), with 21 U.S.C.A. §§ 341-501-1 (West
See Benesh & Faber, supra note 198.
See Adams, supra note 1.
See Science and Research, supra note 28.
See, e.g., Lipton & Abrams, supra note 154.
See, e.g., DRAFT GUIDANCE FOR INDUSTRY, supra note 90.
See, e.g., Schaffer, supra note 73, at 203-04.
See Adams, supra note 1.
See Lipton & Abrams, supra note 154.
See Benesh & Faber, supra note 198.
See Lipton & Abrams, supra note 154.

2018]

MAKEUP CALL

247

Women have used cosmetic products long before the FD&C
Act's enactment in 1938. 249 In the eighty years since, despite scientific advancements, research, and adverse reports, the Act's cosmetics
subchapter remains unaltered.250 The introduction in recent years
of cosmetics reform bills in Congress sheds some light on the legislature's intent to finally modernize a law that has provided little, if
any, protection to women since its inception. Hopefully soon, women
will wash their hair and put on their lipstick with the assurance
that they are not their products' first test subjects.
GABRIELLE ERIQUEZ*

249. E.g., Schaffer, supra note 73, at 165.
250. See Benesh & Faber, supra note 198.
* JD Candidate 2019, William & Mary Law School; BS, Biology 2013, College of
William & Mary. The author would like to thank the William & Mary Journal of Race,
Gender, and Social Justice for the selection of this Note for publication.

